<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791630</url>
  </required_header>
  <id_info>
    <org_study_id>2023084</org_study_id>
    <nct_id>NCT05791630</nct_id>
  </id_info>
  <brief_title>The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)</brief_title>
  <acronym>NORWEL</acronym>
  <official_title>The Norwegian World Health Organisation Labour Care Guide Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ostfold Hospital Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Appropriate and timely care during birth is critical to the survival and health of women and&#xD;
      their babies. In 2020, the World Health Organization (WHO) presented the Labour Care Guide&#xD;
      (LCG) as the new recommended tool for monitoring birth and assessing progression, replacing&#xD;
      the WHO partograph. This evidence-based guide was designed to ensure improved quality and&#xD;
      safety of care, and to avoid unnecessary interventions during birth. The LCG was developed to&#xD;
      be used in all settings globally, but it has only been tested in health facilities in South&#xD;
      America, Asia and Africa, while it has not been tested in high-income settings. Implementing&#xD;
      a new guideline for monitoring birth is a comprehensive operation that will affect both the&#xD;
      national economy, health systems, and individual patients; therefore, further research on the&#xD;
      possible advantages is needed before national enrolment. Hence, the trial proposed in this&#xD;
      application is crucial to form the required foundation of knowledge. The trial will be&#xD;
      conducted in labour wards at ten hospitals, covering all health regions in Norway, and the&#xD;
      established Norwegian Research Network for Clinical Studies in Obstetrics (NORBIRTH), with&#xD;
      dedicated local principal investigators, will provide a robust research environment. This&#xD;
      trial will test the effect of the LCG. Results from this trial will provide knowledge needed&#xD;
      to determine a future implementation of the LCG in Norway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large robust trial investigating the effect of the LCG is needed to establish a foundation&#xD;
      of knowledge on which the decision of implementing the LCG on a national level should be&#xD;
      based. The Norwegian WHO LCG trial addresses the WHO research priority question: &quot;What is the&#xD;
      effect of the LCG on processes of care, health, well-being and outcomes during labour and&#xD;
      childbirth?&quot;. The trial will have a special focus on intrapartum caesarean section rates and&#xD;
      experience of labour.&#xD;
&#xD;
      The overall aim of the trial is to test the LCG in an unbiased population in a Norwegian&#xD;
      setting. The project will conduct a nationwide randomized controlled trial (RCT) to test the&#xD;
      effect on labour interventions and maternal and neonatal outcomes compared to the previous&#xD;
      WHO partograph. The Norwegian WHO LCG trial will be conducted through three work packages:&#xD;
      WP1 consists of a feasibility study to develop an electronic version of the LCG, and will&#xD;
      test its validity and usability prior to the planned RCT. WP2 consists of a stepped wedge RCT&#xD;
      to assess the effect of the LCG on labour interventions and maternal and neonatal outcomes.&#xD;
      WP3 consists of a survey to investigate patient reported outcome through the childbirth&#xD;
      experience questionnaire (CEQ).&#xD;
&#xD;
      This is a stepped wedge multicenter cluster randomised non-inferiority trial, to be conducted&#xD;
      within the nationwide NORBIRTH network for clinical obstetric research. The hospitals will&#xD;
      act as clusters and the women as individual participants.&#xD;
&#xD;
      During the trial period all hospitals will use the WHO partograph and the LCG according to&#xD;
      the trial protocol for all women with a planned vaginal delivery, these women constitute the&#xD;
      trial population. Women who want to opt out will not be included in the analyses. Each&#xD;
      hospital has established local research groups which are dedicated to implement the project.&#xD;
      The included hospitals will consent to adhere to the protocol in the trial period and state&#xD;
      that they have the capacity to participate both logistically and practically. Local&#xD;
      coordinators will be appointed with the responsibility of monitoring the trial and secure a&#xD;
      thorough documentation according to the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2024</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Multicenter stepped wedge cluster randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrapartum cesarean section</measure>
    <time_frame>18 months</time_frame>
    <description>the rate of intrapartum cesarean sections (ICS), presented in numbers and percentages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Instrumental vaginal delivery</measure>
    <time_frame>18 months</time_frame>
    <description>The rate of instrumental vaginal delivery, presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perineal tears</measure>
    <time_frame>18 months</time_frame>
    <description>Perineal tears will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post partum hemorrhage</measure>
    <time_frame>18 months</time_frame>
    <description>Post partum hemorrhage will be presented in numbers and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>18 months</time_frame>
    <description>Estimated blood loss will be presented in ml of blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>18 months</time_frame>
    <description>The need for blood transfusion will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The use of oxytocin</measure>
    <time_frame>18 months</time_frame>
    <description>The use of oxytocin will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of oxytocin</measure>
    <time_frame>18 months</time_frame>
    <description>The dosages of oxytocin will be presented in milli units (m/U)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxytocin</measure>
    <time_frame>18 months</time_frame>
    <description>The duration of oxytocin will be presented in hours and minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initiation of oxytocin</measure>
    <time_frame>18 months</time_frame>
    <description>Initiation of oxytocin will be presented according to cervical dilatation in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Labour duration</measure>
    <time_frame>18 months</time_frame>
    <description>Labour duration will be presented in hours and minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The use of epidural analgesia</measure>
    <time_frame>18 months</time_frame>
    <description>The use of epidural analgesia will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of epidural analgesia</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of epidural analgesia will be presented hours and minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of epidural analgesia</measure>
    <time_frame>18 months</time_frame>
    <description>The initiation of epidural analgesia will be presented according to cervical dilatation presented in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The use of medical pain relief in labour</measure>
    <time_frame>18 months</time_frame>
    <description>The use of medical pain relief will be presented in numbers and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The use of non-medical pain relief in labour</measure>
    <time_frame>18 months</time_frame>
    <description>The use of non-medical pain relief will be presented in numbers and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childbirth experience</measure>
    <time_frame>20 months</time_frame>
    <description>Childbirth experience measured by the childbirth experience questionnaire, CEQ presented in total and mean scores according to the four domains in the CEQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intermittent fetal monitoring</measure>
    <time_frame>18 months</time_frame>
    <description>The use of intermittent fetal monitoring (pinard and doppler) will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous fetal monitoring</measure>
    <time_frame>18 months</time_frame>
    <description>The use of continuous fetal monitoring will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar scores</measure>
    <time_frame>18 months</time_frame>
    <description>Apgar scores 1/5/10 minutes post partum presented in values of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal metabolic acidosis</measure>
    <time_frame>18 months</time_frame>
    <description>Metabolic acidosis will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admittance to Neonatal Intensive Care Unit</measure>
    <time_frame>18 months</time_frame>
    <description>Admittance to the Neonatal Intensive Care Unit will be presented in numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay at neonatal Intensive Care Unit</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of stay at neonatal Intensive Care Unit will be presented days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal gender</measure>
    <time_frame>18 months</time_frame>
    <description>Neonatal gender will be presented by numbers and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth weight</measure>
    <time_frame>18 months</time_frame>
    <description>Neonatal birth weight will be presented in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth head circumference</measure>
    <time_frame>18 months</time_frame>
    <description>Neonatal head circumference will be presented in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>18 months</time_frame>
    <description>Neonatal morbidity will be presented in numbers and percentages.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Continuous support in labour</measure>
    <time_frame>18 months</time_frame>
    <description>Continuous support will be presented as yes/no and according to cervical dilatation</description>
  </other_outcome>
  <other_outcome>
    <measure>Birthing position</measure>
    <time_frame>18 months</time_frame>
    <description>The birthing position will registered and presented in numbers and percentages</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal presentation</measure>
    <time_frame>18 months</time_frame>
    <description>The fetal delivery presentation will be registered and presented in numbers and percentages</description>
  </other_outcome>
  <other_outcome>
    <measure>Perineal support</measure>
    <time_frame>18 months</time_frame>
    <description>Perineal support will be registered in numbers and percentages</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin-to-skin-contact</measure>
    <time_frame>18 months</time_frame>
    <description>Immediate skin-to-skin-contact will be registered as yes/no and time for immediate skin-to-skin-contact will be presented in hours and minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Breast feeding</measure>
    <time_frame>18 months</time_frame>
    <description>Breastfeeding will be presented as number and percentages</description>
  </other_outcome>
  <other_outcome>
    <measure>The use of formula</measure>
    <time_frame>18 months</time_frame>
    <description>The use of formula will be registered as number and percentages</description>
  </other_outcome>
  <other_outcome>
    <measure>Usability of the Labour Care Guide</measure>
    <time_frame>24 months</time_frame>
    <description>Midwives' and doctors' experience with LCG use assessed through a customized questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20636</enrollment>
  <condition>Labor Dystocia</condition>
  <condition>Labor Complication</condition>
  <condition>Labor Onset and Length Abnormalities</condition>
  <condition>Labor (Obstetrics)--Complications</condition>
  <condition>Experience, Life</condition>
  <condition>Progression</condition>
  <condition>Cesarean Section Complications</condition>
  <condition>Apgar; 4-7 at 1 Minute</condition>
  <arm_group>
    <arm_group_label>WHO partograph</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>all study sites use the WHO partograph as standard care in the first step of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WHO labour care guide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study sites will cross over to the intervention according to randomization and use the LCG for assessing labour progression and wellbeing in labour</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>the labour care guide (LCG)</intervention_name>
    <description>The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour</description>
    <arm_group_label>WHO labour care guide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women in active labour&#xD;
&#xD;
          -  Labour and delivery at study sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women in labour and delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stine Bernitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ostfold Hospital Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stine Bernitz, PhD</last_name>
    <phone>+4790944715</phone>
    <email>stine.bernitz@oslomet.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecka Dalbye, PhD</last_name>
    <phone>+4745247873</phone>
    <email>rebecka.dalbye@oslomet.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ostfold Hospital Trust</name>
      <address>
        <city>Gre√•ker</city>
        <state>Ostfold</state>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebecka Dalbye, PhD</last_name>
      <phone>+4745247873</phone>
      <email>rebda@oslomet.no</email>
    </contact>
    <contact_backup>
      <last_name>Waleed Ghanima, PhD</last_name>
      <phone>+4741303440</phone>
      <email>waleed.ghanima@so-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ostfold Hospital Trust</investigator_affiliation>
    <investigator_full_name>Stine Bernitz</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystocia</mesh_term>
    <mesh_term>Obstetric Labor Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will be shared according to demand and aim</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>from onset of trial until five years after the trial has ended</ipd_time_frame>
    <ipd_access_criteria>if the purpose is stated and acceptable and presented by scientific personnel</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

